Advances in the pathogenesis and possible treatments for multiple hereditary exostoses from the 2016 international MHE conference
- 3 November 2017
- journal article
- research article
- Published by Taylor & Francis in Connective Tissue Research
- Vol. 59 (1) , 85-98
Abstract
Multiple hereditary exostoses (MHE) is an autosomal dominant disorder that affects about 1 in 50,000 children worldwide. MHE, also known as hereditary multiple exostoses (HME) or multiple osteochondromas (MO), is characterized by cartilage-capped outgrowths called osteochondromas that develop adjacent to the growth plates of skeletal elements in young patients. These benign tumors can affect growth plate function, leading to skeletal growth retardation, or deformations, and can encroach on nerves, tendons, muscles, and other surrounding tissues and cause motion impairment, chronic pain, and early onset osteoarthritis. In about 2–5% of patients, the osteochondromas can become malignant and life threatening. Current treatments consist of surgical removal of the most symptomatic tumors and correction of the major skeletal defects, but physical difficulties and chronic pain usually continue and patients may undergo multiple surgeries throughout life. Thus, there is an urgent need to find new treatments to prevent or reverse osteochondroma formation. The 2016 International MHE Research Conference was convened to provide a forum for the presentation of the most up-to-date and advanced clinical and basic science data and insights in MHE and related fields; to stimulate the forging of new perspectives, collaborations, and venues of research; and to publicize key scientific findings within the biomedical research community and share insights and relevant information with MHE patients and their families. This report provides a description, review, and assessment of all the exciting and promising studies presented at the Conference and delineates a general roadmap for future MHE research targets and goals.Keywords
Funding Information
- Lubkin Fund of The Philadelphia Foundation
- National Institute of Arthritis, Musculoskeletal and Skin Diseases (AR069987)
This publication has 86 references indexed in Scilit:
- Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromasScientific Reports, 2013
- Glycobiology and the Growth PlateJournal of Pediatric Orthopaedics, 2011
- Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bonesBone, 2011
- Wnt Signaling Gradients Establish Planar Cell Polarity by Inducing Vangl2 Phosphorylation through Ror2Developmental Cell, 2011
- A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostosesProceedings of the National Academy of Sciences, 2010
- A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytesProceedings of the National Academy of Sciences, 2010
- Heparan Sulfate 2-O-Sulfotransferase Is Required for Triglyceride-rich Lipoprotein ClearanceJournal of Biological Chemistry, 2010
- Regulation of articular chondrocyte proliferation and differentiation by indian hedgehog and parathyroid hormone–related protein in miceArthritis & Rheumatism, 2008
- Heparan sulphate proteoglycans fine-tune mammalian physiologyNature, 2007
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971